Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Caribou Biosciences (CRBU) Shares Outstanding (Weighted Average) (2020 - 2025)

Caribou Biosciences has reported Shares Outstanding (Weighted Average) over the past 6 years, most recently at $93.4 million for Q4 2025.

  • Quarterly Shares Outstanding (Weighted Average) rose 3.4% to $93.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $93.4 million through Dec 2025, up 3.4% year-over-year, with the annual reading at $93.4 million for FY2025, 3.4% up from the prior year.
  • Shares Outstanding (Weighted Average) was $93.4 million for Q4 2025 at Caribou Biosciences, roughly flat from $93.0 million in the prior quarter.
  • Over five years, Shares Outstanding (Weighted Average) peaked at $93.4 million in Q4 2025 and troughed at $9.5 million in Q1 2021.
  • The 5-year median for Shares Outstanding (Weighted Average) is $67.6 million (2023), against an average of $67.6 million.
  • Year-over-year, Shares Outstanding (Weighted Average) soared 537.37% in 2022 and then grew 1.06% in 2023.
  • A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $31.7 million in 2021, then surged by 92.02% to $60.8 million in 2022, then grew by 21.39% to $73.8 million in 2023, then grew by 22.37% to $90.3 million in 2024, then grew by 3.4% to $93.4 million in 2025.
  • Per Business Quant, the three most recent readings for CRBU's Shares Outstanding (Weighted Average) are $93.4 million (Q4 2025), $93.0 million (Q3 2025), and $92.9 million (Q2 2025).